AVDL | Avadel Pharmaceuticals plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	1.34
Implied Volatility	78.14%
IV Rank	63.25%
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	1996-06-07

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	154
Country	Ireland
Website	AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL's peers: NBIX, DCPH, IRWD, ALKS, ITCI, DVAX, DERM, EVOK, JUPW, AQST, EGRX, ANIP, AGRX, ASRT, AMRX, ACRX, LFCR, AYTU, DRRX, ESPR, LNTH, SIGA

*Chart delayed

Analyzing fundamentals for AVDL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak. For more detailed analysis please see AVDL Fundamentals page.

Watching at AVDL technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AVDL Technicals page.